Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02269280 · ClinicalTrials.gov registry record · Phase 2
Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)
A Phase 2 study of Leukemia, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 185
- Enrollment target
- 6
- Study locations
NCT02269280 is a Phase 2 study of Leukemia that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 185 participants, below the 486-participant average among 233 other Leukemia trials with a reported enrollment target (62% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT02269280, a Phase 2 study of Leukemia, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 185 participants
- Enrollment target
- 6
- Study locations
Study Summary
The goal of this clinical research study is to compare how 2 different drugs, decitabine and azacitidine, when given on a shorter than standard dosing schedule, may help to control MDS. The safety of each study drug given on these schedules will also be studied. This is an investigational study. Decitabine and azacitidine are both FDA approved and commercially available for use in patients with MDS. Giving these drugs on a different schedule than is standard is considered investigational. The study doctor can tell you how the study drugs are designed to work.
Conditions Studied
Interventions
- OTHER Best Supportive Care (BSC)
- DRUG Azacitidine (AZA) Days 1 - 3
- DRUG Decitabine (DAC)
- DRUG Azacitidine (AZA) Days 1 - 5
Study Locations (6)
Florida
- Moffitt Cancer Center - Tampa
Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center - Baltimore
Massachusetts
- Dana-Farber Cancer Institute - Boston
New York
- NYP/Weill Cornell Medical Center - New York
Ohio
- Cleveland Clinic Foundation - Cleveland
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2014-10-13 |
| Est. Completion | 2024-07-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02269280
The ClinicalTrials.gov registry entry for NCT02269280 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 185 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 486-participant average among 233 other Leukemia trials with a reported enrollment target (62% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 4 interventions - of which Best Supportive Care (BSC) is the first listed.
NCT02269280 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Florida, Maryland, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02269280 about?
NCT02269280 is a clinical study titled "Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)". The goal of this clinical research study is to compare how 2 different drugs, decitabine and azacitidine, when given on a shorter than standard dosing schedule, may help to control MDS. The safety of each study drug given on these schedules will also be studied. This is an investigational study. De...
What is the current status of trial NCT02269280?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 185 participants. The study started on 2014-10-13. Estimated completion is 2024-07-25.
What conditions does trial NCT02269280 study?
This clinical trial studies the following conditions: Leukemia.
What interventions are being tested in trial NCT02269280?
The interventions under investigation include: Best Supportive Care (BSC) (OTHER), Azacitidine (AZA) Days 1 - 3 (DRUG), Decitabine (DAC) (DRUG), Azacitidine (AZA) Days 1 - 5 (DRUG).
Who is sponsoring clinical trial NCT02269280?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02269280 being conducted?
This trial has 6 study locations across Florida, Maryland, Massachusetts, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
RECRUITING · Phase 2
-
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
RECRUITING · Phase 2
-
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 2
-
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
RECRUITING · Phase 2
-
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.